Market overview
The global autoinjector market is worth USD 3.7 bn in 2026 and is forecast to reach USD 9.5 bn by 2036, growing at a 10.0% CAGR. United States is the largest country market and Disposable is the largest by type segment.
| Scope | Spring-loaded single-dose and multi-dose autoinjector devices for self-administration of injectable drugs, including disposable and reusable devices sold to drug makers and patients. |
|---|---|
| Industry | Healthcare |
| Value 2025 | USD 3.3 bn |
| Value 2026 | USD 3.7 bn |
| Value 2036 | USD 9.5 bn |
| CAGR 2026-2036 | 10.0% |
| Volume 2026 | 729 million units |
| Volume 2036 | 2,090 million units |
| Average price 2026 | USD 5.03 per unit |
| Report price | Starts from USD 1,999 |
| Published | November 2026 |
Request a free sample of this report
Autoinjector market size and forecast, 2026-2036
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Year | Market value |
|---|---|
| 2026 | USD 3.7 bn |
| 2027 | USD 4.0 bn |
| 2028 | USD 4.4 bn |
| 2029 | USD 4.9 bn |
| 2030 | USD 5.4 bn |
| 2031 | USD 5.9 bn |
| 2032 | USD 6.5 bn |
| 2033 | USD 7.1 bn |
| 2034 | USD 7.9 bn |
| 2035 | USD 8.6 bn |
| 2036 | USD 9.5 bn |
Autoinjector market segmentation
By type
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Disposable | 75.0% | 74.2% | USD 2.7 bn | 9.9% |
| Reusable | 17.0% | 14.0% | USD 623 mn | 7.9% |
| Smart and connected | 8.0% | 11.8% | USD 293 mn | 14.4% |
By therapy
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Autoimmune | 28.0% | 24.0% | USD 1.0 bn | 8.3% |
| Diabetes and obesity | 30.0% | 38.6% | USD 1.1 bn | 12.8% |
| Anaphylaxis | 10.0% | 6.2% | USD 366 mn | 4.8% |
| Migraine and neurology | 12.0% | 12.9% | USD 440 mn | 10.8% |
| Cardiovascular and lipid | 8.0% | 9.4% | USD 293 mn | 11.8% |
| Other | 12.0% | 8.9% | USD 440 mn | 6.8% |
By end user
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Home self-administration | 72.0% | 77.7% | USD 2.6 bn | 10.8% |
| Hospitals and clinics | 20.0% | 17.2% | USD 733 mn | 8.3% |
| Emergency use | 8.0% | 5.2% | USD 293 mn | 5.3% |
By drug class
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Biologics | 44.0% | 47.0% | USD 1.6 bn | 10.7% |
| GLP-1 agonists | 20.0% | 22.0% | USD 733 mn | 11.1% |
| Insulin analogues | 12.0% | 10.0% | USD 440 mn | 8.0% |
| Emergency drugs | 12.0% | 9.0% | USD 440 mn | 6.9% |
| Others therapies | 12.0% | 12.0% | USD 440 mn | 10.0% |
By usage
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Disposable | 72.0% | 66.0% | USD 2.6 bn | 9.1% |
| Reusable | 20.0% | 22.0% | USD 733 mn | 11.1% |
| Smart connected | 8.0% | 12.0% | USD 293 mn | 14.6% |
Top 25 countries for autoinjector by revenue
Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 75.5% of 2026 revenue and the 25 countries below together hold 93.9%.
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| # | Country | Value 2026 | Share 2026 | Value 2036 | CAGR 2026-36 |
|---|---|---|---|---|---|
| 1 | United States | USD 1.5 bn | 40.0% | USD 3.8 bn | 10.1% |
| 2 | Germany | USD 220 mn | 6.0% | USD 523 mn | 9.1% |
| 3 | Japan | USD 183 mn | 5.0% | USD 399 mn | 8.1% |
| 4 | China | USD 183 mn | 5.0% | USD 684 mn | 14.1% |
| 5 | United Kingdom | USD 147 mn | 4.0% | USD 352 mn | 9.2% |
| 6 | France | USD 147 mn | 4.0% | USD 352 mn | 9.2% |
| 7 | Switzerland | USD 110 mn | 3.0% | USD 238 mn | 8.0% |
| 8 | Italy | USD 110 mn | 3.0% | USD 247 mn | 8.4% |
| 9 | Canada | USD 110 mn | 3.0% | USD 266 mn | 9.2% |
| 10 | Spain | USD 92 mn | 2.5% | USD 219 mn | 9.1% |
| 11 | Ireland | USD 89 mn | 2.4% | USD 225 mn | 9.8% |
| 12 | Singapore | USD 87 mn | 2.4% | USD 248 mn | 11.0% |
| 13 | Netherlands | USD 71 mn | 1.9% | USD 181 mn | 9.7% |
| 14 | Denmark | USD 69 mn | 1.9% | USD 176 mn | 9.8% |
| 15 | Belgium | USD 57 mn | 1.6% | USD 145 mn | 9.8% |
| 16 | Sweden | USD 54 mn | 1.5% | USD 137 mn | 9.8% |
| 17 | Brazil | USD 43 mn | 1.2% | USD 124 mn | 11.1% |
| 18 | India | USD 41 mn | 1.1% | USD 117 mn | 11.0% |
| 19 | Poland | USD 38 mn | 1.1% | USD 109 mn | 11.0% |
| 20 | Australia | USD 29 mn | 0.8% | USD 72 mn | 9.7% |
| 21 | Taiwan | USD 23 mn | 0.6% | USD 65 mn | 11.0% |
| 22 | Mexico | USD 20 mn | 0.5% | USD 56 mn | 11.0% |
| 23 | Israel | USD 18 mn | 0.5% | USD 45 mn | 9.8% |
| 24 | Austria | USD 17 mn | 0.5% | USD 44 mn | 9.8% |
| 25 | Saudi Arabia | USD 16 mn | 0.5% | USD 48 mn | 11.2% |
| Rest of world | USD 225 mn | 6.1% | USD 585 mn | 10.0% |
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
Competitive landscape
Group 1: Global leaders
- SHL Medical
- Ypsomed
- Becton Dickinson
- West Pharmaceutical Services
- Nemera
Group 2: Regional and specialist players
- Owen Mumford
- Haselmeier
- Bespak
- Phillips-Medisize
- Gerresheimer
- Jabil
Group 3: Emerging and niche players
- Credence MedSystems
- Subcuject
- Elcam Drug Delivery Devices
Research methodology
Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the autoinjector market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.
The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 10.0% is calculated from the resulting values.
The market is divided by type, by therapy, by end user, by drug class, by usage. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.
Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.
Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.
Frequently asked questions
How big is the autoinjector market?
The global autoinjector market is estimated at USD 3.3 bn in 2025 and USD 3.7 bn in 2026.
How fast will the autoinjector market grow?
It is forecast to reach USD 9.5 bn by 2036, a compound annual growth rate of 10.0% from 2026, an increase of USD 5.8 bn.
Which country is the largest market for autoinjector?
United States is the largest market by revenue at USD 1.5 bn in 2026, 40.0% of the global total. The three largest countries together hold 51.0%.
Which country is growing fastest?
Among the ten largest markets, China is growing fastest at 14.1% a year from 2026 to 2036.
Which autoinjector segment is largest?
In the by type split, Disposable is the largest segment with 75.0% of 2026 revenue.
Who are the leading autoinjector companies?
Global leaders include SHL Medical, Ypsomed, Becton Dickinson, West Pharmaceutical Services.
Need the full report?
Request a sample to see the structure, tables and country detail.
Request a free sampleRelated markets in Healthcare
- Pharmaceutical SerializationUSD 3.7 bn · 9.0% CAGR
- ImmunohistochemistryUSD 3.5 bn · 8.0% CAGR
- Healthcare Provider Workflow OptimizationUSD 3.4 bn · 10.5% CAGR
- Biospecimen LogisticsUSD 3.9 bn · 9.0% CAGR
- CapsuleUSD 3.4 bn · 6.5% CAGR
- Neurorehabilitation TechnologyUSD 3.4 bn · 9.0% CAGR
- Behavioral Health Continuum SolutionsUSD 4.0 bn · 10.5% CAGR
- Nuclear MedicineUSD 4.0 bn · 6.2% CAGR